Mesalamine API segmentation by type distinguishes oral and rectal dosage‑form categories, each with distinct production and pricing dynamics. Oral formulations—primarily tablets, capsules, and granules—command roughly 80 % of API consumption because they dominate first‑line therapy for ulcerative colitis and are preferred for patient adherence. Within this group, tablets represent the largest sub‑type (≈45 % of oral volume) due to their manufacturing simplicity and cost efficiency, while granules (≈25 %) are favored for dose titration in pediatric and maintenance regimens, and capsules (≈10 %) occupy niche markets requiring delayed‑release profiles. Rectal formulations, comprising suppositories and enemas, account for the remaining 20 % of API demand, serving patients with distal disease where topical delivery yields superior mucosal concentrations. The synthetic mesalamine route, which employs direct sulfonation of 5‑ASA, supplies about 65 % of total API, offering higher purity and lower impurity profiles; the remaining 35 % derives from bioequivalent generic processes that leverage legacy patents to reduce cost. This type‑based market taxonomy informs capacity planning, as manufacturers must balance high‑volume tablet lines with specialized equipment for granule and rectal product synthesis.
